	Application No.	Applicant(s)
Notice of Allowability	10/524,798	CLARK ET AL.
	Examiner	Art Unit
	Rebecca L. Anderson	1626
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the amendment filed 25 June 2007.		
2. The allowed claim(s) is/are <u>1-5,15 and 16</u> .		
3. ☑ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☑ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received.		
 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the 		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF		
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
 1) ☐ hereto or 2) ☐ to Paper No./Mail Date (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of 		
Paper No./Mail Date		
ldentifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
•		
	·	
		•
Attachment(s) 1. Notice of References Cited (PTO-892)	5. Notice of Informal I	Patent Application
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary	/ (PTO-413),
3. Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Da 7.	
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	8 🕅 Examiner's Statem	ent of Reasons for Allowance
of Biological Material	9. Other	
	o	
•		
	•	

Art Unit: 1626

DETAILED ACTION

Claims 1-5, 15 and 16 are currently pending in the instant application, appear allowable over the prior art of record and have been renumbered as claims 1-7.

Applicants' amendment has overcome the 35 USC 112 1st paragraph rejection of claims 10-14 and the double patenting rejection of clams 1-5 and 10-15 is withdrawn as the instantly claimed invention potently inhibit both the norepinephrine and serotonin transporters and the compounds in the copending application are selective for norepinephrine transporter only. The modification of the stereochemistry of the (2S,2S') compounds claimed in 10/524,650 to provide the (2R,2R') compounds of the present invention introduces potent serotonin transporter inhibitory activity which would not be suggested to the skilled artisan.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance. This invention relates to products of the formula (I) and a method of treating persistent pain. The novel and nonobvious aspect of this invention involves the phenylthio group. The closest prior art of record, WO 01-01973, which discloses reboxetine, a highly selective norepinephrine reuptake inhibitor compared to serotonin, fails to teach or suggest applicants' instantly claimed invention.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1626

Conclusion

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (571) 272-0696. Mrs. Anderson can normally be reached Monday through Friday from 6:00am until 2:30pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Rebecca Anderson/ Primary Examiner, AU 1626

21 August 2007

Rebecca Anderson
Primary Examiner
Art Unit 1626, Group 1620
Technology Center 1600